The business is improving; the common claim still needs a lower price. Full tariff and financing bridges, debt-like claims and potential dilution matter more than the adjusted EPS headline.
Analyst judgments, not company guidance. Same claim bridge isolates business-value outcomes.
| Measure | Value |
|---|---|
| Bear | 1.00 |
| Base | 3.50 |
| Bull | 8.00 |
| Weighted | 3.65 |
| Reference | 5.99 |
| Scenario | Probability | 12-month value | vs $5.99 | What has to happen | The arithmetic |
|---|---|---|---|---|---|
| Bear | 30% | $1.00 | −83% | Retail pressure and refinancing absorb the recovery. | $504.844M enterprise less $438.844M claims, divided by 66M model shares. |
| Base | 50% | $3.50 | −42% | Modest growth and controlled costs; base rounded from $3.60 route blend. | $669.844M enterprise less $438.844M claims, divided by 66M model shares. |
| Bull | 20% | $8.00 | +34% | Stronger demand and brand mix produce substantially higher durable margins. | $966.844M enterprise less $438.844M claims, divided by 66M model shares. |
| 30% × $1 + 50% × $3.50 + 20% × $8 = $3.65. Conditional entry $2.45, exactly 30% below base. | |||||
| Signpost | Now (Q2 FY2026) | Green if | Red if | Next check |
|---|---|---|---|---|
| Retail comps | −2.6% | At least 0% | Below −4% | Next Q3; review Dec 15, 2026 |
| Full ex-refund gross margin | 45.14% | At least 45.5% | Below 44% | Next Q3; review Dec 15, 2026 |
| Full ex-refund EBIT | $19.187M | At least $35M | Below $20M | Next Q3; review Dec 15, 2026 |
| Liquidity and claims | $51.591M cash; $455.435M debt + finance leases | Cash and claims improve | Cash below $35M or debt claims above $475M | Next Q3; review Dec 15, 2026 |
| Potential ownership | 66M gross model | Stable claim count | Above 69M | Next Q3 filing; review Dec 15, 2026 |
No verified prior packet signpost scorecard claimed. Review dates are analytical deadlines, not confirmed company reporting dates.
Designer Brands has a real operating improvement, an unusually complicated tariff windfall and an expensive capital structure. Those can all be true together. Our call is SELL, conviction 3/5, high uncertainty, with $3.50 base fair value against the September 10 reference price of $5.99. The three-route valuation blends to $3.60 before rounding. The stock therefore needs a stronger durable recovery than our base case delivers; an earnings increase alone does not establish a bargain for common shareholders.
The saved quote rose 14.75% from $5.22 on September 10, with 1.62M shares traded. We have the same-day release and market record, but have not independently established the exact first public-release clock or isolated every other cause of trading. This is a same-day move, not a precise event-study claim. The provider market capitalization uses a share count that differs from the filing, and its descriptive profile still carries obsolete three-segment language. We use primary filings for the business and share analysis.
| Date | Close |
|---|---|
| 2024-09-03 | $6.13 |
| 2024-12-02 | $5.52 |
| 2025-03-06 | $4.10 |
| 2025-06-05 | $3.64 |
| 2025-09-05 | $4.73 |
| 2025-12-04 | $4.71 |
| 2026-03-09 | $6.02 |
| 2026-06-08 | $8.88 |
| 2026-09-08 | $5.20 |
A low share price is not a low enterprise valuation. At $5.99 and our deliberately gross 66M modeling denominator, common equity represents $395.34M. The modeled debt, finance leases, minority claim and cash reserve, net of recorded cash, add another $438.844M. The resulting $834.184M business-value hurdle is materially larger than the quoted equity headline. Changing the potential share count changes that hurdle, which is why the packet shows both reported and modeled ownership rather than substituting one for the other.
| Decision measure | Value |
|---|---|
| Rating / conviction / uncertainty | SELL / 3 of 5 / High |
| Base / scenario-weighted value | $3.50 / $3.65 |
| Route blend before rounding | $3.59996 |
| Reference price / downside to base | $5.99 / 41.6% |
| Conditional entry | $2.45; business conditions must hold |
| Current release; saved FMP quote and analyst valuation. | |
The issuer calls this Q2 FY2026: thirteen weeks ended August 1, 2026, with the release dated September 10. Fiscal labels matter: FY2025 ended January 31, 2026. Revenue fell 1.2% to $730.631M even as reported operating profit more than doubled. GAAP diluted EPS rose to $0.31 from the restated $0.21. The issuer’s adjusted EPS was $0.34 versus $0.33, but that adjustment does not remove all tariff benefits and adds back income attributed to the redeemable minority interest. Neither the growth headline nor the adjusted label is sufficient by itself.
| Q2 result, $M except EPS | FY2026 | FY2025 restated |
|---|---|---|
| Sales | 730.631 | 739.762 |
| Gross profit | 365.355 | 322.493 |
| Operating expenses | 313.412 | 297.462 |
| Operating equity income | 2.78 | 2.578 |
| Operating profit | 54.723 | 26.143 |
| Consolidated net income | 20.417 | 10.874 |
| Income attributed to Topo minority | 2.86 | 0.339 |
| Income attributable to DBI | 17.557 | 10.535 |
| Diluted EPS / issuer adjusted EPS | $0.31 / $0.34 | $0.21 / $0.33 |
| Current 10-Q; non-GAAP tables. | ||
The full first half is less dependent on the latest quarter than the headline suggests. Revenue was essentially flat at $1,426.981M. Operating profit excluding the entire tariff-cost recovery was $38.057M, compared with $18.236M reported in the restated prior half. Q1 supplied a substantial improvement. Q2 alone, however, produced $19.187M operating profit after the same complete refund removal, below $26.143M a year earlier. This combination argues for a recovery that needs confirmation, not for either dismissing the improvement or projecting the Q2 windfall indefinitely.
| Measure | Value |
|---|---|
| Q2 FY2024 | 771.90 |
| Q3 FY2024 | 777.19 |
| Q4 FY2024 | 713.57 |
| Q1 FY2025 | 686.91 |
| Q2 FY2025 | 739.76 |
| Q3 FY2025 | 752.41 |
| Q4 FY2025 | 713.59 |
| Q1 FY2026 | 696.35 |
| Q2 FY2026 | 730.63 |
| Quarter | Revenue $M | Gross margin | EBIT $M | Owner NI $M | GAAP EPS |
|---|---|---|---|---|---|
| Q2 FY2024 | 771.900 | 43.99% | 28.589 | 13.824 | 0.24 |
| Q3 FY2024 | 777.194 | 42.95% | 22.816 | 13.012 | 0.24 |
| Q4 FY2024 | 713.572 | 39.60% | −25.854 | −38.168 | −0.80 |
| Q1 FY2025 | 686.909 | 42.87% | −7.907 | −17.816 | −0.37 |
| Q2 FY2025 | 739.762 | 43.59% | 26.143 | 10.535 | 0.21 |
| Q3 FY2025 | 752.411 | 45.14% | 42.663 | 18.215 | 0.35 |
| Q4 FY2025 | 713.589 | 42.42% | −14.220 | −19.992 | −0.40 |
| Q1 FY2026 | 696.350 | 45.28% | 18.870 | 1.159 | 0.02 |
| Q2 FY2026 | 730.631 | 50.01% | 54.723 | 17.557 | 0.31 |
| Primary 10-Qs and FY2025 release. Gross classification is recast; Q1/Q2 FY2025 use current duty-restated comparisons. Other older earnings remain as then reported; do not sum mixed-basis quarters to claim a restated annual. | |||||
There are two different historical comparability changes. Store selling and occupancy costs were moved from cost of sales to operating expenses, lifting the displayed gross margin without changing operating profit. Separately, previously underreported Topo import duties caused restatement of selected prior earnings and balance-sheet rows. Our gross-margin series uses the current expense classification. The current filing supplies corrected Q1 and Q2 FY2025 comparisons, but does not provide a complete revised annual allocation for every older period. We identify that limitation rather than manufacture balancing amounts.
Designer Brands combines a footwear retailer with owned and licensed brands. Retail includes DSW in the United States and Canada, The Shoe Co. and Rubino. Brand Portfolio supplies wholesale customers, direct consumers and DBI’s own stores. The integrated model can improve assortment, distribution and licensing economics, but intercompany sales are not incremental consolidated revenue. The FY2025 annual report combined the former U.S. and Canada retail segments; current comparative segment figures are recast into Retail and Brand Portfolio.
| Q2 business, $M | Current | Prior |
|---|---|---|
| Retail external revenue | 671.062 | 686.003 |
| Brand external revenue | 59.569 | 53.759 |
| Brand intercompany sales | 26.71 | 19.398 |
| Brand total segment sales | 86.279 | 73.157 |
| Consolidated external sales | 730.631 | 739.762 |
| Retail segment profit | 62.027 | 68.709 |
| Brand segment profit | 0.979 | −4.046 |
| Note 11 segment reporting. Do not add gross Brand sales to Retail without eliminating intercompany sales. | ||
Retail external revenue declined 2.2%, with comparable sales down 2.6%. Brand external revenue grew 10.8%; the faster 17.9% segment-sales increase includes intercompany business. The improvement in Brand profit from a loss to a small gain is useful evidence, because segment profit excludes all of the tariff recovery. It is also modest relative to Retail’s $6.682M segment-profit decline. The first half is stronger for Brand Portfolio, with $16.402M profit against a $2.100M prior loss, but the parent still has corporate costs and ownership claims to fund.
| Measure | Value |
|---|---|
| Women non-athletic | −3.82 |
| Men non-athletic | −1.86 |
| Kids non-athletic | −2.00 |
| Athletic | −12.14 |
| Accessories and other | 4.88 |
Athletic footwear sales fell $12.144M within Retail while accessories and other increased $4.880M. This mix warns against treating growth in a successful owned athletic brand as proof that the entire athletic retail category is healthy. National brands remain important to traffic and purchasing power. The annual filing says the three largest national-brand suppliers supplied 24% of purchases and Brand Portfolio supplied 10%. A recovery depends on customer relevance and inventory productivity as well as product ownership.
| Annual operating context | Source-backed fact |
|---|---|
| Brand sourcing by units, FY2025 | China 60%; Cambodia 19%; Vietnam 15%; other 6% |
| Retail VIP sales share | 89% in FY2025 versus 86% |
| Workforce | Approximately 13,000 at January 31, 2026 |
| ABG-Camuto interest | 40%; licensing and equity income are part of the economics |
| FY2025 annual report. Customer membership is not a contractual recurring-revenue backlog. | |
The business has valuable customer access, recognizable brands and a distribution network. It also competes with brands selling directly, large online retailers and specialist footwear chains. Membership sales show repeat engagement, but do not create subscription revenue or protect margins from promotions. The model therefore allows modest sales growth while requiring better cost conversion, rather than attributing software-like durability or recurring margins to a discretionary retailer.
The tariff bridge is the central accounting issue. The company recognized $35.536M of tariff-cost recoveries in gross profit. Its adjusted gross-profit reconciliation removes only $15.336M, the amount associated with funding part of the Investor interest payment. The remaining $20.200M is still inside issuer-adjusted gross profit and operating profit. Accordingly, reported gross margin is 50.0%, issuer-adjusted margin is 47.9%, and the margin after removing the full tariff-cost recovery is approximately 45.14%. These are three distinct measures.
| Q2 gross-profit bridge | USD M |
|---|---|
| Reported gross profit | 365.355 |
| Issuer adjustment removed | −15.336 |
| Issuer adjusted gross profit | 350.019 |
| Additional retained refund to remove | −20.2 |
| Fully ex-recovery gross profit | 329.819 |
| Fully ex-recovery margin | 45.14% |
| Prior restated margin | 43.59% |
| Release gross-profit reconciliation; Note 11 full recovery. Full removal is Charged Alpha arithmetic, not an issuer non-GAAP measure. | |
| Measure | Value |
|---|---|
| Reported | 50.01 |
| Issuer adjusted | 47.91 |
| Full refund removed | 45.14 |
| Prior restated | 43.59 |
Even the fully adjusted comparison is not perfectly “clean” economic profit: it retains the company’s ordinary estimates, compensation, costs and operating equity income. Its purpose is narrow and reproducible: remove the full recorded tariff-cost benefit. The resulting gross-profit improvement is $7.326M, but operating expenses rise $15.950M. Lower impairment expense and other operating lines partly offset that pressure. Q2 operating profit after full recovery removal falls $6.956M from the restated prior quarter. That is a more demanding test than simply observing higher issuer-adjusted earnings.
| Reported EBIT to fully ex-refund EBIT | Q2 $M | H1 $M |
|---|---|---|
| Reported operating profit | 54.723 | 73.593 |
| Entire tariff-cost recovery | −35.536 | −35.536 |
| Fully ex-recovery operating profit | 19.187 | 38.057 |
| Issuer adjusted operating profit | 39.387 | 58.765 |
| Prior restated reported operating profit | 26.143 | 18.236 |
| H1 issuer adjustment also adds back $0.508M restructuring. Different measures answer different questions. | ||
| Measure | Value |
|---|---|
| Q2 reported | 54.723 |
| Q2 issuer adjusted | 39.387 |
| Q2 full refund removed | 19.187 |
| Prior Q2 restated | 26.143 |
Before the tariff court ruling, the company sold rights to $18.3M of potential claims for $2.2M cash. During Q2 it received about $36.8M from Customs and remitted $18.3M to the unrelated Investor. The filing treats the remittance as financing: approximately $2.2M principal and $16.1M interest. Selling contingent claims before resolution can transfer legal and timing risk, but the subsequent accounting must reflect the contractual payoff. We do not characterize all $36.8M as freely retained cash, nor subtract the remittance again from the August cash balance.
| Issuer Q2 adjusted net-income reconciliation | USD M |
|---|---|
| Attributable GAAP net income | 17.557 |
| COGS recovery adjustment | −15.336 |
| Related nonoperating interest adjustment | −0.761 |
| Investor interest addback | 16.097 |
| Foreign-exchange adjustment | 0.006 |
| Redeemable minority income addback | 2.86 |
| Tax adjustment | −1.195 |
| Issuer adjusted net income | 19.228 |
| Exact non-GAAP table. The three tariff financing adjustments net to zero before tax; this is not a full removal of the net windfall. | |
The EPS denominator and ownership scope matter as much as the numerator. Quarterly diluted weighted shares rose to 55.974M from 49.734M. GAAP income attributed to DBI is after the $2.860M Topo minority attribution; company adjusted net income adds that minority line back. An investor should not value the adjusted EPS as if it automatically represented earnings owned entirely by the public common shares. Our enterprise approaches include the consolidated operating business, then explicitly deduct a modeled minority claim.
Topo’s historical duty error is separate from the IEEPA refund transaction. The company found incorrect import-duty rates affecting pre- and post-acquisition periods, with an estimated five-year obligation of about $8.4M including interest. It considered the prior-period errors individually immaterial but their aggregate correction material to the current first quarter, so it revised comparative statements. That is a control and diligence question, not a reason to label every restated dollar a current cash expense or to erase the duty liability from the capital analysis.
| Restatement illustration, $M | Previously reported | Current comparative |
|---|---|---|
| Q2 FY2025 attributable net income | 10.827 | 10.535 |
| H1 FY2025 attributable net loss | −6.597 | −7.281 |
| Jan31 accrued expenses | 170.014 | 178.43 |
| Jan31 redeemable NCI | 5.274 | 1.616 |
| Jan31 equity | 282.486 | 280.0 |
| Prior H1 CFO | 1.077 | 1.077 |
| Note 12. Cash-flow restatement reallocates reconciling lines without changing total prior H1 CFO. | ||
Current receivables include $25.3M of insured legal settlement obligations paired with related accrued liabilities. That pairing explains part of the rising balance and prevents treating every receivable dollar as a customer-demand signal. It also does not make collection and settlement timing disappear. The allowance for credit losses is only $0.431M against gross receivables of $80.828M, while $26.818M of customer receivables carry third-party payment guarantees. The mix needs to be read before interpreting a simple receivables-to-sales ratio.
The annual auditor is Deloitte & Touche, with an audit report dated March 30, 2026. That report applies to the annual statements as issued; it is not a separate audit opinion on the September release or a guarantee against later corrections. Inventory valuation remains judgment-sensitive: the annual report estimates a 10% increase in markdown, shrink and aging reductions would raise cost of sales by roughly $4M. We retain inventory risk, stock compensation and ordinary restructuring pressure in the economic assessment. The question is whether improved margins survive those costs, not whether every noncash line can be added away.
| Provider and primary-source policy | Treatment |
|---|---|
| Earnings consensus | Saved provider update is after the release; clean preprint EPS basis and share adjustment not established |
| Adjusted EPS beat/miss | No fabricated comparable-consensus beat claimed |
| Historical fundamentals | Actual SEC rows govern; provider originals retained |
| Old gross-margin series | Recast to current cost presentation using primary comparative rows |
| Equity investment income | Retained in EBIT; no separate investment-book-value addition |
| Raw URLs, hashes and row headers are retained with the source audit. | |
H1 operating cash flow was $48.236M and cash capital expenditure was $22.251M, producing $25.985M ordinary free cash flow. Management identifies a rounded $20.7M favorable operating-cash contribution from the refund net of the Investor interest remittance. Subtracting that rounded figure leaves roughly $5.3M FCF, but this is an illustration, not certified normalized cash: related tax payments, claim timing and working-capital movements are not isolated to a precise tax-adjusted basis. The $2.2M Investor principal is a financing flow, distinct from the operating-interest payment.
| H1 CFO bridge | USD M |
|---|---|
| Consolidated net income | 23.871 |
| Depreciation and amortization | 28.267 |
| Stock compensation | 14.52 |
| Deferred taxes | 5.864 |
| Equity income reversal | −4.926 |
| Equity distributions received | 5.965 |
| Other noncash | 0.528 |
| Receivables cash use | −18.714 |
| Inventory cash use | −32.872 |
| Prepaids cash source | 1.598 |
| Payables cash source | 21.519 |
| Accrual cash source | 7.133 |
| Operating lease net cash use | −4.517 |
| Operating cash flow | 48.236 |
| Cash capital expenditure | −22.251 |
| CFO less cash capex | 25.985 |
| Cash-flow statement. SBC is a cash reconciliation addback here, but remains an economic compensation cost in valuation. | |
| Measure | Value |
|---|---|
| Q2 FY2024 | 27.99 |
| Q3 FY2024 | −19.19 |
| Q4 FY2024 | 58.12 |
| Q1 FY2025 | −27.59 |
| Q2 FY2025 | 11.92 |
| Q3 FY2025 | 57.50 |
| Q4 FY2025 | 36.43 |
| Q1 FY2026 | −31.90 |
| Q2 FY2026 | 57.89 |
| Quarter | CFO $M | Capex $M | FCF $M | D&A $M | SBC $M |
|---|---|---|---|---|---|
| Q2 FY2024 | 41.578 | 13.590 | 27.988 | 16.448 | 5.865 |
| Q3 FY2024 | −9.761 | 9.429 | −19.190 | 15.748 | 3.571 |
| Q4 FY2024 | 70.099 | 11.981 | 58.118 | 15.246 | 3.668 |
| Q1 FY2025 | −20.366 | 7.229 | −27.595 | 14.796 | 6.103 |
| Q2 FY2025 | 21.443 | 9.524 | 11.919 | 14.868 | 5.960 |
| Q3 FY2025 | 66.530 | 9.031 | 57.499 | 14.715 | 3.383 |
| Q4 FY2025 | 42.253 | 5.821 | 36.432 | 14.700 | 3.544 |
| Q1 FY2026 | −22.033 | 9.869 | −31.902 | 14.380 | 6.468 |
| Q2 FY2026 | 70.269 | 12.382 | 57.887 | 13.887 | 8.052 |
| Quarter derivations and original YTD headers retained in historical_financials.json. | |||||
Inventory consumed $32.872M of H1 cash while receivables consumed $18.714M; payables and accruals supplied cash. Ending inventory of $594.688M is lower than the prior-year $610.876M but higher than the January seasonal low. Those comparisons answer different questions. Cash increased only $0.720M to $51.591M after investing, financing and currency movements. The cash balance already reflects the completed refund and Investor remittance. Future working-capital releases are not an automatic source of value in our forecast.
| Enterprise-to-common bridge | USD M |
|---|---|
| ABL including FILO | 309.723 |
| Term loan face principal | 116.25 |
| Total face funded debt | 425.973 |
| Inferred current finance leases | 29.462 |
| Analyst Topo minority allowance | 15.0 |
| Analyst operating cash reserve | 20.0 |
| Recorded cash credit | −51.591 |
| Net enterprise claims deducted | 438.844 |
| Debt face exceeds carrying debt by $2.914M deferred fees. Finance lease estimate = January $30.791M less $1.329M H1 principal; no new additions disclosed. FX/modification uncertainty remains. | |
| Measure | Value |
|---|---|
| ABL including FILO | 309.723 |
| Term loan face | 116.250 |
| Inferred finance leases | 29.462 |
The ordinary revolver rate was 6.0%; the term loan carried 10.8% cash interest and a higher effective rate including fees. The term loan matures in June 2028, and the revolving facility has an earlier-maturity provision linked to it despite a later outside date. The $29.5M FILO sits inside total ABL debt and must not be added twice. Availability of roughly $146.2M under the borrowing base is a contingent funding resource, not cash or an asset to add to fair value. Both facilities are secured and subject to liquidity-linked covenants.
Finance lease obligations belong with debt-like claims because finance lease amortization remains in operating profit while its interest is below EBIT. Operating leases of $785.957M are treated differently: rent remains in forecast operating costs, so adding that liability to the same valuation would mix lease conventions. This does not mean stores are free or leases harmless. H1 operating-lease cash payments were $106.670M; finance leases used another $1.363M operating interest and $1.329M financing principal. A $20M cash reserve is our seasonal funding assumption, with zero and $40M sensitivities; it is not a company-designated restriction.
| Measure | Value |
|---|---|
| Reported A+B | 51.038 |
| A+B plus current RSUs | 64.447 |
| Gross model | 66.000 |
| Stress share case | 69.000 |
| Common ownership and possible awards | Millions |
|---|---|
| Reported outstanding A + B | 51.038 |
| Quarter weighted basic / diluted | 50.894 / 55.974 |
| Current time-based / performance RSUs | 9.760 / 3.649 |
| Outstanding plus all current RSUs | 64.447 |
| January director units | 1.1; already in basic EPS; overlap unresolved |
| Gross modeling denominator | 66.0 |
| Notes 4–6 and annual compensation note. 66M is an overlap-possible allowance, not exact new issuance or GAAP diluted shares; no exercise proceeds credited. | |
Class A and B have the same economic rights and B can convert one-for-one, but B carries eight votes per share against one for A. Schottenstein affiliates control roughly 64% of votes with about 27% economic ownership. Treasury shares are excluded from outstanding common. The 66M model deliberately allows for substantial awards without claiming every performance unit vests or adding January director units twice to an EPS-derived denominator. Compensation stays in economic margins as an ongoing labor cost. Topo’s remaining 20.6% has a performance-linked put/call; the $6.232M book amount is remeasured and is not a guaranteed eventual settlement. Our $15M allowance, about 2.4 times book, is a stress assumption with a broad sensitivity, not contractual precision.
All three routes use the August 1 financial anchor. The DCF models only the remaining half of FY2026 and then FY2027–FY2030, with cash at 0.5, 1.5, 2.5, 3.5 and 4.5 years. We compare that value with the later September 10 market quote without inventing an interim cash bridge. Already realized H1 cash is in the balance sheet and is not forecast again. Taxes, reinvestment and working capital are explicit, and stock compensation and operating rent remain in profit. The annual guide is a reasonableness check; our normalized operating forecasts are not company guidance.
| DCF period | $M revenue | EBIT margin | EBIT | D&A | Reinvest | NWC use | FCFF | Years |
|---|---|---|---|---|---|---|---|---|
| H2 FY2026 | 1480.153 | 1.49% | 22.000 | 28.000 | 25.000 | 0.000 | 18.400 | 0.5 |
| FY2027 | 2965.277 | 2.80% | 83.028 | 56.000 | 52.000 | 2.000 | 60.119 | 1.5 |
| FY2028 | 3024.583 | 3.20% | 96.787 | 57.000 | 54.000 | 2.000 | 68.751 | 2.5 |
| FY2029 | 3085.074 | 3.50% | 107.978 | 58.000 | 56.000 | 2.000 | 75.584 | 3.5 |
| FY2030 | 3146.776 | 3.80% | 119.577 | 59.000 | 58.000 | 2.000 | 82.704 | 4.5 |
| FCFF = EBIT × 70% + D&A − reinvestment − NWC cash use. Analyst assumptions; no automatic seasonal release. | ||||||||
FY2026 sales start at the midpoint of the issuer’s flat-to-1% growth range, or $2,907.134M, leaving $1,480.153M in H2 after actual H1. We assume $22M H2 operating profit excluding refunds, producing $60.057M for the full year. Prior H2 reported EBIT was $28.443M on its then-reported basis, so this assumption does not require an immediate record finish. H2 D&A of $28M, reinvestment of $25M and no working-capital release yield $18.4M unlevered cash. Tax at 30% is a normalized assumption below the current 37.7% H1 effective rate, making sustained nondeductible costs an adverse sensitivity.
The more demanding step is FY2027: sales grow 2%, but EBIT rises to $83.028M and margin reaches 2.8%. That requires about $22.97M more profit than our FY2026 core model. If the roughly $58M incremental revenue contributes 45% gross profit, it supplies about $26M before incremental operating costs; thus the forecast permits only a modest cost increase and requires strong cost control. This is a recovery assumption, not simple top-line extrapolation. By FY2030, margin reaches 3.8%, still below a retail business with exceptional economics but materially above recent DBI annual outcomes.
| Measure | Value |
|---|---|
| H2 FY2026 | 18.40 |
| FY2027 | 60.12 |
| FY2028 | 68.75 |
| FY2029 | 75.58 |
| FY2030 | 82.70 |
| Valuation route | Enterprise $M | Common / share | Weight |
|---|---|---|---|
| DCF | 726.974 | $4.366 | 50% |
| Economic NOPAT | 663.455 | $3.403 | 30% |
| Revenue EV | 569.587 | $1.981 | 20% |
| Each deducts the same $438.844M current claim bridge and divides by 66M shares. Blend $3.59996; base rounds to $3.50 at $0.25 increments. | |||
| Measure | Value |
|---|---|
| DCF | 4.366 |
| Economic NOPAT | 3.403 |
| Revenue EV | 1.981 |
| Weighted route blend | 3.600 |
The DCF uses a 12% discount rate and 2% perpetual growth. Terminal value contributes most of enterprise value, so the terminal cash margin deserves more scrutiny than a neat near-term spreadsheet. The economic-profit route capitalizes FY2028 after-tax operating profit at 13 times and discounts it 2.5 years. That is an enterprise NOPAT multiple, not a common-equity P/E; it therefore still requires the funded-claim deduction. The revenue route uses 0.25 times FY2028 sales, equivalent to 7.81 times the modeled EBIT before discount. These two terminal cross-checks intentionally give no separate credit for interim cash generation. They are corroborating lenses, not statistically independent forecasts.
| Capital sensitivity | Route-weighted $/share |
|---|---|
| Shares 51.038M | 4.655 |
| Shares 64.447M | 3.687 |
| Shares 66.000M | 3.600 |
| Shares 69.000M | 3.443 |
| Cash reserve $0M | 3.903 |
| Cash reserve $20M | 3.600 |
| Cash reserve $40M | 3.297 |
| Topo claim $6.232M | 3.733 |
| Topo claim $15.000M | 3.600 |
| Topo claim $30.000M | 3.373 |
| Topo claim $50.000M | 3.070 |
| One assumption changes at a time. Reported outstanding shares are a sensitivity, not a replacement for award analysis. | |
| DCF discount rate | Terminal growth | DCF $/share |
|---|---|---|
| 10% | 0% | 5.024 |
| 10% | 2% | 7.268 |
| 10% | 3% | 8.871 |
| 12% | 0% | 2.961 |
| 12% | 2% | 4.366 |
| 12% | 3% | 5.302 |
| 14% | 0% | 1.493 |
| 14% | 2% | 2.436 |
| 14% | 3% | 3.037 |
| The DCF-only range is wider than the blended base. Low discount rates are not guaranteed by current financing access. | ||
The reference price requires $834.184M enterprise value under the model’s capital assumptions. In the economic-NOPAT route, that implies roughly 4.02% FY2028 EBIT margin rather than our 3.2%, at the same revenue, tax, multiple and discount rate. Alternatively it requires a larger multiple, less dilution, lower claims or a combination. This is the constructive bull case: a stronger brand mix and healthier retail demand can create operating leverage. The bear case is that customer softness and refinancing costs absorb the recovery while the common claim remains a thin residual.
Our bear/base/bull equity values are $1/$3.50/$8 with subjective 30%/50%/20% weights, giving $3.65 weighted value. Their enterprise values are $504.844M/$669.844M/$966.844M under the same claim bridge. Holding claims constant isolates operating outcomes; an actual strong Topo outcome could also enlarge the minority settlement, while a weak case could worsen financing. The conditional $2.45 entry is exactly 30% below base. It is an analytical review threshold, not an automatic order: cash availability, duty resolution and recurring profit must remain consistent with the thesis.
Management raised FY2026 sales guidance from minus 1% to plus 1% growth to flat through plus 1%, and lifted adjusted EPS from $0.28–$0.38 to $0.47–$0.52. The sales midpoint increases only half a percentage point; the EPS midpoint rises 50% from $0.33 to $0.495. The improvement is substantial on the issuer’s definition, but the footnote excludes selected tariff-financing items rather than the entire refund benefit. The guidance also excludes specified minority, foreign-exchange, restructuring, duty-interest and tax items. Calling it a pure recurring-EPS upgrade would overstate what the source establishes.
| FY2026 guide | Prior June release | Current September release |
|---|---|---|
| Sales growth | −1% to +1% | 0% to +1% |
| Adjusted diluted EPS | $0.28–$0.38 | $0.47–$0.52 |
| Revenue midpoint algebra | $2,892.671M | $2,907.134M |
| EPS midpoint | $0.33 | $0.495 |
| Prior guide; current guide and exclusions. Revenue algebra applies growth to FY2025 actual sales. | ||
H1 issuer-adjusted EPS is $0.41, but subtracting it from the annual EPS range does not produce exact standalone H2 EPS because weighted share counts and exclusions can change. As a rough hurdle only, the annual midpoint leaves $0.085 beyond H1 on the issuer’s EPS basis. We do not translate that into a certified H2 profit forecast. The stronger analytic check is the full source-backed revenue and operating-profit bridge, including the fact that the last two fourth quarters had operating losses even when the broader fall season supported cash generation.
| Comparison | Wall Street | Charged Alpha |
|---|---|---|
| Rating | Current comparable consensus unverifiable | SELL; 3/5 conviction |
| Target / fair value | UBS $6 dated Sep1 provider record; preprint | Base $3.50; Aug1 financial anchor |
| Alignment | Dated target above our value | More cautious on common residual value |
| FMP saved target-news data; complete broker model and current rating not obtained. No invented consensus rating. | ||
The latest saved target record is a September 1 UBS reduction to $6 from $7.50. Older observations refer to different information sets. The provider also returns a “Hold” aggregate without a sufficiently clear date or active coverage universe, and annual estimates often show one analyst. We retain those raw records but do not pass them off as a verified current multi-analyst consensus. The saved earnings record lists adjusted EPS and revenue estimates updated after the release; that timing and the uncertain adjustment basis prevent a clean preprint beat/miss claim.
Douglas Howe is chief executive and Sheamus Toal is chief financial officer in the current filings. The investment case depends on management’s ability to convert assortment and sourcing changes into recurring cash while honoring secured lenders and minority holders. We give credit for lower funded debt and a better first half, while recognizing that a portion of cash improvement came from a legal recovery and that the gross-margin presentation changes can obscure the underlying comparison. Corporate costs, award growth and acquisition accounting remain relevant tests of execution.
| Three annual periods | Revenue $M | Gross margin | EBIT $M | Owner NI $M | CFO $M | Capex $M | FCF $M |
|---|---|---|---|---|---|---|---|
| FY2023 | 3074.976 | 43.06% | 72.401 | 29.062 | 162.399 | 54.997 | 107.402 |
| FY2024 | 3009.262 | 42.73% | 34.933 | −10.549 | 82.236 | 50.891 | 31.345 |
| FY2025 | 2892.671 | 43.57% | 47.764 | −8.374 | 109.860 | 31.605 | 78.255 |
| FY2025 annual comparative statements. FY2023 has 53 weeks versus 52 in FY2024 and FY2025. Annual earnings are as then reported; later duty revisions not completely allocated. | |||||||
Revenue has declined across these three annual periods, while cash flow varies with inventory, receivables and tax timing. The FY2024 cash-flow statement included a $44.476M income-tax-receivable release, illustrating why cash conversion should be assessed across years. Acquisitions used $127.496M in FY2023 and $16.144M in FY2024. They are separate from ordinary capex and therefore not inside the simple FCF chart, but they were real uses of capital. A brand strategy should earn back its purchase price and minority obligations, not merely expand segment revenue.
Repurchases used $102.188M in FY2023 and $68.553M in FY2024, with no cash repurchases in FY2025 and treasury shares unchanged through the current half. H1 dividends cost $4.961M and share-award tax withholding used $4.298M. The board declared another $0.05 dividend per share, payable October 7 to September 24 holders. Those commitments may be modest individually, but they compete with seasonal inventory, debt service and reinvestment. With dual-class voting control, public investors have limited influence over that allocation.
| Measure | Value |
|---|---|
| FY2023 | 107.40 |
| FY2024 | 31.34 |
| FY2025 | 78.25 |
The annual report’s Topo measurement policy adjusts the redeemable interest for attributable earnings and, when applicable, changes needed to reach the higher of redemption value or carrying value. That means H1 minority attribution cannot safely be annualized as ordinary recurring earnings. The source does not give us a complete contractual future payout formula. Our explicit claim allowance and sensitivity reflect that uncertainty. We would prefer a transparent settlement timetable and reconciliation over a valuation that silently assumes all consolidated brand profits belong to common shareholders.
The strongest counterargument to our Sell is that the recovery is already visible beneath the windfall. Fully ex-refund gross margin improves, Brand Portfolio’s first-half profit turns positive, and face funded debt falls sharply year over year. If retail traffic stabilizes and fixed costs grow slowly, a small margin increase on nearly $3B of sales can add tens of millions to operating profit. Our bull case recognizes that leverage. A bearish view that ignores the real first-half improvement would be incomplete.
The main downside risk is a mismatch between cash needs and reported profit. Inventory must be purchased before it sells, secured borrowing availability can change with collateral, and June 2028 refinancing approaches before a distant terminal value is earned. Tariff policy and remaining import-duty corrections can alter sourcing costs or cash timing. The company has not isolated every tax consequence of the refund financing for a precise normalized cash measure. An attractive quarterly EPS figure therefore cannot replace a liquidity bridge.
| Risk | Economic consequence | Evidence to watch |
|---|---|---|
| Retail demand and markdowns | Gross-profit gains lost to clearance or traffic declines | Comps, inventory aging, full ex-refund margin |
| Funding and finance leases | Common residual squeezed by debt-like obligations | Borrowing base, rates, covenant headroom, lease principal |
| Topo minority settlement | Consolidated brand success may enlarge another holder’s claim | Put/call disclosures and remeasurement |
| Award issuance | More claims on the same business value | Current units, settlements, basic/diluted share bridge |
| Duty and settlement accounting | Accrual/receivable timing can obscure cash | Restatement roll-forward and actual payments |
| Forward tests are analytical judgments, not statements that a breach has occurred. | ||
Valuation risk also runs in both directions. The $20M cash reserve may be too large if cash proves genuinely surplus, or too small in a difficult seasonal cycle. The 66M denominator is deliberately gross and may exceed eventual issued shares if awards lapse; it may be insufficient if new grants or capital raising continue. The Topo allowance is not a certified contract value. Sensitivities show how these choices affect the common residual. High uncertainty is a statement about the width of plausible outcomes, not permission to hide the assumptions.
Our next review deadline is December 15, 2026, intended to capture the next quarterly filing; this is not a company-confirmed release date. A constructive result would combine nonnegative Retail comparable sales, gross margin of at least 45.5% after removing all new tariff recoveries, and underlying operating profit of at least $35M. Any new windfall must be bridged separately before applying those tests. We would also want funded debt and finance lease claims to fall through cash generation rather than a temporary working-capital squeeze.
Adverse evidence includes Retail comps below minus 4%, fully ex-recovery gross margin below 44%, or underlying quarterly EBIT below $20M. Cash below $35M without a clear seasonal funding explanation, total face debt plus estimated finance leases above $475M, or new potential share claims taking the gross allowance above 69M would require another valuation pass. These are monitoring thresholds, not loan covenants. A better price alone cannot fix a deteriorating business, while better durable margins could lift value before the stock reaches our conditional entry.
| Review test | Current baseline | Positive | Adverse |
|---|---|---|---|
| Retail comps | −2.6% | At least 0% | Below −4% |
| Full ex-refund gross margin | 45.14% | At least 45.5% | Below 44% |
| Full ex-refund EBIT | $19.187M Q2 | At least $35M next Q3 | Below $20M |
| Cash | $51.591M | Stable with explained seasonal funding | Below $35M unexplained |
| Face debt + finance leases | $455.435M estimated | Declining with cash generation | Above $475M |
| Gross potential-share model | 66M assumption | No unexplained growth | Above 69M |
| Review by December 15, 2026. Company reporting date not verified; thresholds are Charged Alpha tests. | |||
This packet does not claim a verified track record against an earlier DBI research packet. Prior-period media identity was reconciled for admission, but a prior frozen signpost scorecard was not available to this research pass. We start with a transparent current baseline. The call is falsifiable: improving customer demand and economic margins, controlled dilution and a clearer financing path can overturn it. A repeat of adjusted EPS growth fueled by recoveries or minority addbacks would not, by itself, do so.
Primary evidence governs the analysis: the September 10 earnings release and current 10-Q, the June quarter, the FY2025 annual report, and quarterly and annual releases covering nine quarters and three complete fiscal years. Original downloaded HTML and submission documents are retained with source URLs, fetch times and SHA-256 hashes. Parsed tables preserve their actual row headers and dates. Current filing comparisons override older provider rows when restatements or cost classifications differ.
| Primary source | Period / role |
|---|---|
| September 10 release | Q2 FY2026 print, guidance and exact adjustments |
| Current Form 10-Q | August 1 balance sheet, cash flow, Investor, duties, shares and segments |
| June release | Prior FY2026 guidance |
| FY2025 Form 10-K | Three annual statements, finance leases, Topo rights, awards and control |
| FY2025 full-year release | Q4 actual EPS and consistent quarterly comparatives |
| All underlying historical filing URLs and hashes are retained in the source manifest. | |
Amounts in the working financial history are thousands of U.S. dollars unless labeled otherwise; display tables generally convert to millions. Quarterly cash figures are derived from cumulative cash-flow statements by subtraction. Fourth-quarter earnings use full-year less nine-month figures on a consistent reporting basis, while fourth-quarter EPS comes from the actual release because EPS cannot generally be subtracted across weighted share counts. We do not arbitrarily scale provider fundamentals, treat an annual row as a quarter, or fill unavailable corrected history with estimates.
The three valuation routes are independent arithmetic checks on the same operating judgment, so their weights are editorial choices rather than statistical probabilities. Scenario weights are also subjective. The enterprise bridge uses debt face value, an inferred finance-lease roll-forward, a minority allowance and a seasonal cash reserve, with common shares modeled gross. Capitalized operating equity income is not supplemented by investment book value. Operating rent remains in EBIT; finance lease debt is included. These conventions make the residual claim understandable even where the filing leaves a future settlement amount uncertain.
No original broker research model, verified current consensus-rating population or authoritative transcript of the current call was obtained. Management commentary here comes from actual releases and filings. The current quote and target-news records are saved provider data, with their dates and limitations. Visuals use the channel’s established studio assets and self-authored financial tables; no unverified third-party photograph, logo license or media credit is asserted. Raw source retention allows a reviewer to reproduce the numbers without relying on the prose.